 |
|
Prostate Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
6. Cediranib for Androgen-Independent Prostate Cancer
(Posted: 04/29/2008) - In this trial, men with metastatic, androgen-independent prostate cancer whose cancer has continued to progress on docetaxel will take oral cediranib daily.
7. Bevacizumab for Hormone-Refractory Prostate Cancer
(Posted: 09/05/2006, Updated: 12/26/2007) - In this trial, men with hormone-refractory prostate cancer that has spread (metastasized) will receive standard chemotherapy with the drugs docetaxel and prednisone. Half of the participants will be randomly assigned to additionally receive treatment with a monoclonal antibody called bevacizumab.
8. Pomegranate Juice for PSA-only Prostate Cancer Recurrence
(Posted: 09/25/2007) - In this clinical trial, researchers are exploring the potential of pomegranate juice to slow or reverse increasing PSA levels in men who have undergone treatment for localized prostate cancer.
9. Comparing Radiation Therapies for Prostate Cancer
(Posted: 06/26/2007) - In this trial, men with favorable-risk, localized prostate cancer will be randomly assigned to receive conventionally fractionated radiation therapy over the course of about eight weeks (41 daily treatments) or hypofractionated radiotherapy over a five-and-a-half week period (28 daily treatments).
10. Sorafenib for Metastatic Prostate Cancer
(Posted: 01/23/2007) - In this clinical trial, patients with metastatic, androgen-independent prostate cancer will be treated with sorafenib, a small-molecule inhibitor that blocks the activity of several cancer-related proteins.
< Previous 1 2 3 4 Next >
|
|
|
